275 related articles for article (PubMed ID: 25747985)
1. Pharmacological characterization of [trans-5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl]acetic acid monobenzenesulfonate (JTT-553), a novel acyl CoA:diacylglycerol transferase (DGAT) 1 inhibitor.
Tomimoto D; Okuma C; Ishii Y; Akiyama Y; Ohta T; Kakutani M; Ohkuma Y; Ogawa N
Biol Pharm Bull; 2015; 38(2):263-9. PubMed ID: 25747985
[TBL] [Abstract][Full Text] [Related]
2. JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice.
Tomimoto D; Okuma C; Ishii Y; Kobayashi A; Ohta T; Kakutani M; Imanaka T; Ogawa N
J Pharmacol Sci; 2015 Sep; 129(1):51-8. PubMed ID: 26354408
[TBL] [Abstract][Full Text] [Related]
3. A pharmacologic increase in activity of plasma transaminase derived from small intestine in animals receiving an acyl CoA: diacylglycerol transferase (DGAT) 1 inhibitor.
Yokoyama H; Kobayashi A; Kondo K; Oshida SI; Takahashi T; Masuyama T; Shoda T; Sugai S
J Toxicol Sci; 2018; 43(2):135-157. PubMed ID: 29479035
[TBL] [Abstract][Full Text] [Related]
4. A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity.
Yamamoto T; Yamaguchi H; Miki H; Kitamura S; Nakada Y; Aicher TD; Pratt SA; Kato K
Eur J Pharmacol; 2011 Jan; 650(2-3):663-72. PubMed ID: 21034741
[TBL] [Abstract][Full Text] [Related]
5. Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets.
Yamamoto T; Yamaguchi H; Miki H; Shimada M; Nakada Y; Ogino M; Asano K; Aoki K; Tamura N; Masago M; Kato K
Eur J Pharmacol; 2010 Aug; 640(1-3):243-9. PubMed ID: 20478303
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans.
Maciejewski BS; LaPerle JL; Chen D; Ghosh A; Zavadoski WJ; McDonald TS; Manion TB; Mather D; Patterson TA; Hanna M; Watkins S; Gibbs EM; Calle RA; Steppan CM
Am J Physiol Gastrointest Liver Physiol; 2013 Jun; 304(11):G958-69. PubMed ID: 23558010
[TBL] [Abstract][Full Text] [Related]
7. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
Hata T; Mera Y; Tadaki H; Kuroki Y; Kawai T; Ohta T; Kakutani M
Diabetes Obes Metab; 2011 May; 13(5):446-54. PubMed ID: 21255216
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.
Fox BM; Sugimoto K; Iio K; Yoshida A; Zhang JK; Li K; Hao X; Labelle M; Smith ML; Rubenstein SM; Ye G; McMinn D; Jackson S; Choi R; Shan B; Ma J; Miao S; Matsui T; Ogawa N; Suzuki M; Kobayashi A; Ozeki H; Okuma C; Ishii Y; Tomimoto D; Furakawa N; Tanaka M; Matsushita M; Takahashi M; Inaba T; Sagawa S; Kayser F
J Med Chem; 2014 Apr; 57(8):3464-83. PubMed ID: 24670009
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein.
Mera Y; Odani N; Kawai T; Hata T; Suzuki M; Hagiwara A; Katsushima T; Kakutani M
J Pharmacol Exp Ther; 2011 Feb; 336(2):321-7. PubMed ID: 20974698
[TBL] [Abstract][Full Text] [Related]
10. The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes.
Chitraju C; Walther TC; Farese RV
J Lipid Res; 2019 Jun; 60(6):1112-1120. PubMed ID: 30936184
[TBL] [Abstract][Full Text] [Related]
11. Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
Cao J; Zhou Y; Peng H; Huang X; Stahler S; Suri V; Qadri A; Gareski T; Jones J; Hahm S; Perreault M; McKew J; Shi M; Xu X; Tobin JF; Gimeno RE
J Biol Chem; 2011 Dec; 286(48):41838-41851. PubMed ID: 21990351
[TBL] [Abstract][Full Text] [Related]
12. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Choi CS; Savage DB; Kulkarni A; Yu XX; Liu ZX; Morino K; Kim S; Distefano A; Samuel VT; Neschen S; Zhang D; Wang A; Zhang XM; Kahn M; Cline GW; Pandey SK; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Biol Chem; 2007 Aug; 282(31):22678-88. PubMed ID: 17526931
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.
Birch AM; Birtles S; Buckett LK; Kemmitt PD; Smith GJ; Smith TJ; Turnbull AV; Wang SJ
J Med Chem; 2009 Mar; 52(6):1558-68. PubMed ID: 19256504
[TBL] [Abstract][Full Text] [Related]
14. High-content assays for evaluating cellular and hepatic diacylglycerol acyltransferase activity.
Qi J; Lang W; Giardino E; Caldwell GW; Smith C; Minor LK; Darrow AL; Willemsens G; Dewaepenaert K; Roevens P; Linders JT; Liang Y; Connelly MA
J Lipid Res; 2010 Dec; 51(12):3559-67. PubMed ID: 20805092
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.
King AJ; Segreti JA; Larson KJ; Souers AJ; Kym PR; Reilly RM; Collins CA; Voorbach MJ; Zhao G; Mittelstadt SW; Cox BF
Eur J Pharmacol; 2010 Jul; 637(1-3):155-61. PubMed ID: 20385122
[TBL] [Abstract][Full Text] [Related]
16. Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster.
King AJ; Segreti JA; Larson KJ; Souers AJ; Kym PR; Reilly RM; Zhao G; Mittelstadt SW; Cox BF
J Pharmacol Exp Ther; 2009 Aug; 330(2):526-31. PubMed ID: 19478132
[TBL] [Abstract][Full Text] [Related]
17. Enzymatically synthesized glycogen reduces lipid accumulation in diet-induced obese rats.
Furuyashiki T; Ogawa R; Nakayama Y; Honda K; Kamisoyama H; Takata H; Yasuda M; Kuriki T; Ashida H
Nutr Res; 2013 Sep; 33(9):743-52. PubMed ID: 24034574
[TBL] [Abstract][Full Text] [Related]
18. Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.
Yu T; Wu C; Shih N; Li Q; Chan C; Pan H; Yao D; Pan Y; Liang W; Shen L; Zhao H; Li J; Chen S
Bioorg Med Chem Lett; 2018 Jun; 28(10):1686-1692. PubMed ID: 29699923
[TBL] [Abstract][Full Text] [Related]
19. Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying.
Ables GP; Yang KJ; Vogel S; Hernandez-Ono A; Yu S; Yuen JJ; Birtles S; Buckett LK; Turnbull AV; Goldberg IJ; Blaner WS; Huang LS; Ginsberg HN
J Lipid Res; 2012 Nov; 53(11):2364-79. PubMed ID: 22911105
[TBL] [Abstract][Full Text] [Related]
20. Novel acyl coenzyme A (CoA): diacylglycerol acyltransferase-1 inhibitors: synthesis and biological activities of diacylethylenediamine derivatives.
Nakada Y; Aicher TD; Le Huerou Y; Turner T; Pratt SA; Gonzales SS; Boyd SA; Miki H; Yamamoto T; Yamaguchi H; Kato K; Kitamura S
Bioorg Med Chem; 2010 Apr; 18(7):2785-95. PubMed ID: 20207151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
